By Fineline Cube 
Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that the National Medical Products Administration (NMPA) has approved its novel antibody‑drug conjugate (ADC), BL‑M24D1, to enter clinical trials as a monotherapy. The drug is indicated for patients with relapsed or refractory hematological malignancies and advanced solid tumors.
Product Highlights
- Next‑Generation ADC – BL‑M24D1 couples a high‑affinity monoclonal antibody with a potent toxin via a proprietary “linker + toxin” platform.
- Platform Continuity – Shares the same small‑molecule technology as BL‑B16D1 and BL‑M17D1, enabling streamlined manufacturing and accelerated development.
- Broad Indications – Approved for both hematologic and solid‑tumor indications, positioning Biokin to address unmet needs across oncology.
Clinical Development Pathway
| Phase | Status | Key Milestones |
|---|---|---|
| IND Filing | Approved by NMPA | Initiation of Phase I monotherapy trials |
| Pre‑clinical | Completed | Demonstrated target engagement and safety |
| Phase I/II | Planned | Dose‑escalation and early efficacy assessment |
Strategic Impact
- Portfolio Expansion – Adds a first‑in‑class ADC to Biokin’s oncology lineup, enhancing competitive differentiation.
- Platform Validation – Success of BL‑M24D1 reinforces the scalability of Biokin’s “linker + toxin” chemistry.
- Market Opportunity – Addresses a large cohort of patients with limited treatment options for relapsed/refractory disease.
Forward‑Looking Statements
This release contains forward‑looking statements that involve risks and uncertainties. Actual results may differ materially.-Fineline Info & Tech